Monoclonal antibody
Type Whole antibody
Source Human
Target HCSF2
Clinical data
ATC code none
CAS Number 1229575-09-0
ChemSpider none
Chemical and physical data
Formula C6474H10024N1748O2010S42
Molar mass 145.85 kDa

Lenzilumab (INN) is a human monoclonal antibody designed for the treatment of chronic myelomonocytic leukemia.[1][2]

This drug was developed by KaloBios Pharmaceuticals Inc.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lenzilumab, American Medical Association.
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.